Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 25th Preview)
-
Regulatory approval: Merck expands Welireg use for advanced RCC
Merck’s Welireg (belzutifan) received FDA approval for broader use in combination with Eisai’s Lenvima (lenvatinib) to treat certain advanced renal cell carcinoma patients. Merck said the expansion applies to patients with advanced renal cell carcinoma with a clear-cell component, broadening the eligible population beyond the prior indication. Clinically, the move is aimed at increasing access to a regimen that combines a HIF-2α inhibitor with VEGF pathway blockade, reflecting how checkpoint-free combinations continue to reshape first- and subsequent-line planning in RCC. For manufacturers, it also signals continued scale-up opportunities as combination therapy demand grows. The approval reinforces a key theme in oncology approvals: regulators are increasingly willing to expand indications when combination efficacy is supported and safety remains consistent with established class effects.
-
FDA decision: Lyrfigtu wins approval for FGFR2 fusion cholangiocarcinoma
FDA approved Elevar Therapeutics’ Lyrfigtu (lirafugratinib) as a second-line treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. The decision follows results from the multicenter, open-label, single-group REFOCUS trial. In REFOCUS, lirafugratinib achieved a 46% objective response rate, with a median duration of response of 11.8 months, alongside reported progression-free and overall survival outcomes. The FDA label includes warnings aligned with the known FGFR-inhibitor safety profile, including ocular toxicity and hyperphosphatemia. The approval is a meaningful validation for the targeted FGFR2 space in a tumor type where options remain limited for biomarker-selected patients, and it provides a new standard-setting data point for competitors developing next-generation FGFR inhibitors.
-
China-to-Western dealmaking: Lilly signs up to $3.35B with InnoCare
Eli Lilly struck a discovery-stage collaboration with Beijing-based InnoCare Pharma worth up to $3.35 billion, extending Lilly’s China innovation push. Under the agreement, InnoCare will use its drug discovery platform to identify and advance compounds targeting up to five undisclosed targets, with Lilly gaining rights to further develop and commercialize resulting candidates. The deal structure includes up to $100 million in upfront and near-term payments, plus development and milestone payments that could reach $3.25 billion, along with royalties on future sales. The alliance underscores how large-cap pharma is increasingly building discovery pipelines through platform partnerships rather than relying solely on in-house research. For the biotech sector, the agreement is another high-value signal that China-based discovery platforms are securing both strategic and financial commitment from global partners.
-
Biosimilar regulatory roadmap: FDA lays out strategy for interchangeable products
The FDA released a post-workshop strategy document covering Biosimilar User Fee Act (BsUFA) III priorities, including future needs for interchangeable biosimilar development. The agency outlined commitments tied to a scientific workshop on interchangeable products and a subsequent draft strategy to be issued for public comment after the workshop. The document synthesizes feedback from a Sept. 19, 2025 workshop and details how FDA plans to shape its scientific and regulatory priorities as the market for biosimilars expands. For manufacturers, the guidance pipeline impacts development planning, data packages, and interchangeability studies required for broader substitution pathways. Overall, the strategy work aims to reduce regulatory uncertainty around interchangeability—an area that can determine uptake speed once biosimilars reach market.
-
AI-biomed diagnostics: Transparent AI hits 95% accuracy choosing immunotherapy in HNSCC
A study reported a transparent AI model that reached 95% accuracy in selecting between approved PD-1 therapies nivolumab and pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma. The work framed the clinical decision as a difficult judgment call and evaluated AI performance for therapy choice. The “transparent” framing indicates the model’s decision process was designed to be interpretable rather than purely predictive, aligning with growing regulatory and clinician demand for explainability in AI-assisted care. The dataset and evaluation design determine how transferable the result may be, but the headline metric places the approach near the top tier of reported AI diagnostic performance. If validated prospectively, such tools could reduce variability in treatment selection and accelerate personalized decision support in oncology where biomarkers are not always sufficient for nuanced therapy ranking.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.